HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors

被引:69
|
作者
Spence, RA
Anderson, KS
Johnson, KA
机构
[1] PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA
[2] YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA
关键词
D O I
10.1021/bi952058+
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The parameters governing the polymerization mechanism of reverse transcriptase containing the tyrosine to cysteine mutation at position 181 (Y181C) were determined using pre-steady-state techniques. The pathway for single nucleotide incorporation catalyzed by Y181C is similar to that determined for wild-type RT where a rate-limiting conformational change precedes fast chemistry and is followed by slow steady-state release of the primer/template. The Y181C mutant enzyme binds a 25/45-mer duplex DNA tightly with a K-d of 11 nM. However, the Y181C mutation weakens the nucleotide affinity 2-3-fold relative to the wild-type complex. We also determined the parameters governing the mechanism of nonnucleoside inhibitor resistance with Y181C. The K-d value of Nevirapine with the mutant E . DNA complex increased approximately 500-fold. The decreased affinity of Nevirapine for the mutant enzyme is a consequence of a faster inhibitor dissociation rate from the enzyme complex of Y181C relative to that of the wild-type. The E . DNA complex of Y181C may be saturated with Nevirapine, and the I . E . DNA complex is capable of a maximum incorporation rate of 0.1 s(-1) (a 10-fold faster rate than that of the wild-type I . E . DNA complex). The overall two-step binding of nucleotide to Y181C in the presence of Nevirapine remains unaffected.
引用
收藏
页码:1054 / 1063
页数:10
相关论文
共 50 条
  • [31] FEP-guided optimization of azoles as nonnucleoside inhibitors of HIV-1 reverse transcriptase
    Leung, Cheryl S.
    Zeevaart, Jacob G.
    Domaoal, Robert A.
    Bollini, Mariela
    Thakur, Vinay V.
    Anderson, Karen S.
    Jorgensen, William L.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 239
  • [32] Differential Impact of Resistance-Associated Mutations to Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors on HIV-1 Replication Capacity
    Hsieh, Szu-Min
    Pan, Sung-Ching
    Chang, Sui-Yuan
    Hung, Chien-Ching
    Sheng, Wang-Huei
    Chen, Mao-Yuan
    Chang, Shan-Chwen
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (08) : 1117 - 1122
  • [33] HIV-1 reverse transcriptase inhibitors
    El Safadi, Yazan
    Vivet-Boudou, Valerie
    Marquet, Roland
    [J]. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2007, 75 (04) : 723 - 737
  • [34] HIV-1 reverse transcriptase inhibitors
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (03) : 122 - 122
  • [35] HIV-1 reverse transcriptase inhibitors
    Yazan El Safadi
    Valérie Vivet-Boudou
    Roland Marquet
    [J]. Applied Microbiology and Biotechnology, 2007, 75 : 723 - 737
  • [36] Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase
    Tachedjian, G
    Orlova, M
    Sarafianos, SG
    Arnold, E
    Goff, SP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) : 7188 - 7193
  • [37] Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding
    Sluis-Cremer, N
    Temiz, NA
    Bahar, I
    [J]. CURRENT HIV RESEARCH, 2004, 2 (04) : 323 - 332
  • [38] Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs)
    Venkatraj, Muthusamy
    Arien, Kevin K.
    Heeres, Jan
    Dirie, Bertrand
    Joossens, Jurgen
    Van Goethem, Sebastiaan
    Van der Veken, Pieter
    Michiels, Johan
    Velde, Christophe M. L. Vande
    Vanham, Guido
    Lewi, Paw J.
    Augustyns, Koen
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (20) : 5924 - 5934
  • [39] Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations
    Rizzo, RC
    Udier-Blagovic, M
    Wang, DP
    Watkins, EK
    Smith, MBK
    Smith, RH
    Tirado-Rives, J
    Jorgensen, WL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (14) : 2970 - 2987
  • [40] 2ND-GENERATION PETT NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS OF HIV-1
    CANTRELL, A
    ENGELHARDT, P
    HATCH, SD
    JASKUNAS, SR
    JOHANSSON, NG
    JORDAN, CL
    KANGASMETSA, J
    KINNICK, MD
    LIND, P
    MAULDIN, SC
    MORIN, JM
    MUESING, MA
    MUNROE, JE
    NOREEN, R
    OBERG, B
    PRANC, P
    SAHLBERG, C
    TERNANSKY, RJ
    VASILEFF, RT
    VRANG, L
    WEST, SJ
    ZHANG, H
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 94 - MEDI